(MENAFN- EIN Presswire)
Genital Herpes Market Forecast
DelveInsight's Genital Herpes Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.
NEVADA, LAS VEGAS, UNITED STATES, March 27, 2024 /EINPresswire / -- DelveInsight's“Genital Herpes Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Genital Herpes, historical and forecasted epidemiology as well as the Genital Herpes market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Genital Herpes market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Genital Herpes Market Forecast
Some of the key facts of the Genital Herpes Market Report:
- The Genital Herpes market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
- In 2023, there were a total of 225,567,000 prevalent cases of HSV infection in the 7MM (Seven Major Markets), with an expected decline projected throughout the study period spanning from 2020 to 2034.
- In 2023, there were approximately 87,877,000 prevalent cases of HSV infection in the United States.
- In the EU4 and the UK, Germany had the highest number of prevalent cases of HSV infection, totaling approximately 27,959,000 cases, while France had the lowest total prevalence, with around 15,832,000 cases in 2023.
- In August 2022, Rational Vaccines Inc. has initiated an observational clinical study aimed at identifying the fundamental characteristics of patients experiencing recurrent symptomatic herpes simplex virus type 2 infection (HSV-2).
- Genital herpes infection is widespread in the United States. According to a CDC analysis, there were 18.6 million existing cases of HSV-2 in the country in 2018.
- Key Genital Herpes Companies: Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma, Heidelberg ImmunoTherapeutics, AiCuris, and others
- Key Genital Herpes Therapies: Attenuated vaccine against HSV 1&2, HSV“Genital lesions” Skin cream/Lotion, BNT 163, GSK 3943104A, UB 621, HDIT101, Pritelivir, and others
- HSV-2 infection is more prevalent in women compared to men, likely due to the higher transmission rate of genital infection from men to women during penile-vaginal intercourse than from women to men.
- The Genital Herpes market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Genital Herpes pipeline products will significantly revolutionize the Genital Herpes market dynamics.
Genital Herpes Overview
Genital herpes is a sexually transmitted infection (STI) caused by the herpes simplex virus (HSV), primarily HSV-1 or HSV-2. It is typically transmitted through sexual contact, including vaginal, anal, or oral sex with an infected individual. Genital herpes can result in painful sores, blisters, or ulcers in the genital or anal area, as well as other symptoms like itching, burning, and discomfort.
Get a Free sample for the Genital Herpes Market Forecast, Size & Share Analysis Report:
Genital Herpes Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Genital Herpes Epidemiology Segmentation:
The Genital Herpes market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Genital Herpes
- Prevalent Cases of Genital Herpes by severity
- Gender-specific Prevalence of Genital Herpes
- Diagnosed Cases of Episodic and Chronic Genital Herpes
Download the report to understand which factors are driving Genital Herpes epidemiology trends @ Genital Herpes Epidemiology Forecast
Genital Herpes Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Genital Herpes market or expected to get launched during the study period. The analysis covers Genital Herpes market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Genital Herpes Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Genital Herpes Therapies and Key Companies
mRNA 1608: Moderna Therapeutics
Attenuated vaccine against HSV 1&2: Vaxxit
HSV“Genital lesions” Skin cream/Lotion: Nanoviricides
BNT 163: BioNTech
GSK 3943104A: GlaxoSmithKline
UB 621: United BioPharma
HDIT101: Heidelberg ImmunoTherapeutics
Pritelivir: AiCuris
Genital Herpes Market Drivers
Increasing awareness among the population regarding genital herpes infection, availability of high sensitivity and specificity of nucleic acid amplification based kits test type are some of the important factors that are fueling the Genital Herpes Market.
Genital Herpes Market Barriers
However, accessibility of diagnostic services, Insufficient R&D initiatives, pricing pressures, and stringent regulations, lack of novel strategies to prevent or suppress HSV-2 infection and other factors are creating obstacles in the Genital Herpes Market growth.
Scope of the Genital Herpes Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Genital Herpes Companies: Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma, Heidelberg ImmunoTherapeutics, AiCuris, and others
Key Genital Herpes Therapies: Attenuated vaccine against HSV 1&2, HSV“Genital lesions” Skin cream/Lotion, BNT 163, GSK 3943104A, UB 621, HDIT101, Pritelivir, and others
Genital Herpes Therapeutic Assessment: Genital Herpes current marketed and Genital Herpes emerging therapies
Genital Herpes Market Dynamics: Genital Herpes market drivers and Genital Herpes market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Genital Herpes Unmet Needs, KOL's views, Analyst's views, Genital Herpes Market Access and Reimbursement
To know more about Genital Herpes companies working in the treatment market, visit @ Genital Herpes Clinical Trials and Therapeutic Assessment
Table of Contents
1. Genital Herpes Market Report Introduction
2. Executive Summary for Genital Herpes
3. SWOT analysis of Genital Herpes
4. Genital Herpes Patient Share (%) Overview at a Glance
5. Genital Herpes Market Overview at a Glance
6. Genital Herpes Disease Background and Overview
7. Genital Herpes Epidemiology and Patient Population
8. Country-Specific Patient Population of Genital Herpes
9. Genital Herpes Current Treatment and Medical Practices
10. Genital Herpes Unmet Needs
11. Genital Herpes Emerging Therapies
12. Genital Herpes Market Outlook
13. Country-Wise Genital Herpes Market Analysis (2019–2032)
14. Genital Herpes Market Access and Reimbursement of Therapies
15. Genital Herpes Market Drivers
16. Genital Herpes Market Barriers
17. Genital Herpes Appendix
18. Genital Herpes Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here
MENAFN27032024003118003196ID1108025872